Compare Monster Beverage Corp (MNST) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Tilray Brands Inc — how do they compare? Monster Beverage Corp trades at $43.62 (market cap $85.51B), while Tilray Brands Inc trades at $3.63 (market cap $530.54M). The key difference: Monster Beverage Corp is far larger — about 161.2× Tilray Brands Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Tilray Brands Inc for 31 Days on average.
| MNST | TLRY | |
|---|---|---|
Market Cap | $85.51B | $530.54M |
Volume | 8,569,709 | 9,099,075 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $21.00 |
52-Week Low | $33.16 | $3.57 |
Typical Hold Time | 72 Days | 31 Days |
Enterprise Value | $83.81B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $42.88, down 0.86% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported robust Q2 2026 earnings, beating estimates with $0.30 EPS, and maintains impressive profitability metrics including 55.55% gross margin and 23.08% net income margin. Recent news highlights Monster's debt-free balance sheet and international expansion driving 35% overseas sales growth.
While valuation multiples appear elevated (P/E 39.7, P/S 9.18), Monster's consistent earnings beats and analyst consensus price target of $98.22 suggest significant upside potential. Key risks include regulatory challenges in international markets and competitive pressures, but the company's strong cash flow generation and market position support long-term growth prospects.
TLRY trades at $3.715, down 1.72% on the day and near its 52-week low, reflecting persistent bearish technical momentum. The company reported revenue of $821.31M in 2025 but a substantial net loss of -$2.19B, with negative cash flow from operations. Recent quarters show consistent earnings misses versus expectations, though analyst consensus suggests a high price target of $65.01 amid mixed sentiment.
The outlook remains challenged by profitability issues and high debt, but potential catalysts include U.S. cannabis regulatory changes. Investment opportunities hinge on speculative regulatory shifts, while risks include ongoing losses, competitive pressures, and reliance on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
